INT326585

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 7
Disease Relevance 0.86
Pain Relevance 2.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (GYPA, SLC6A3) transport (SLC6A3) aging (SLC6A3)
transmembrane transport (SLC6A3) cytoplasm (SLC6A3) cell death (SLC6A3)
Anatomy Link Frequency
striatum 2
GYPA (Homo sapiens)
SLC6A3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Dopamine 546 98.66 Very High Very High Very High
positron emission tomography 322 97.20 Very High Very High Very High
monoamine 42 96.72 Very High Very High Very High
antagonist 14 96.24 Very High Very High Very High
imagery 161 92.88 High High
Cannabinoid receptor 7 39.56 Quite Low
Substantia nigra 42 5.00 Very Low Very Low Very Low
midbrain 35 5.00 Very Low Very Low Very Low
dopamine receptor 14 5.00 Very Low Very Low Very Low
Neurotransmitter 14 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 462 97.34 Very High Very High Very High
Parkinsonian Disorders 273 82.40 Quite High
Liver Disease 84 60.32 Quite High
Nerve Degeneration 49 52.00 Quite High
Body Weight 28 41.36 Quite Low
Brain Disease 7 28.08 Quite Low
Congenital Anomalies 105 26.52 Quite Low
Tremor 84 5.00 Very Low Very Low Very Low
Hypokinesia 35 5.00 Very Low Very Low Very Low
Drug Induced Neurotoxicity 35 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Because this action on dopaminergic markers is mediated by DAT, these results provide evidence that Mn interacts directly with DAT and are consistent with other studies that indicate an interaction of Mn with DAT (Anderson et al. 2007; Chen et al. 2006; Ingersoll et al. 1999).


Mn Binding (interacts) of DAT
1) Confidence 0.13 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0 Pain Relevance 0.47
Although this is clearly the case in PD patients where the neuropathology is well documented, this cannot be assumed in Mn-exposed subjects because studies have shown that Mn directly interacts with DAT.
Mn Binding (interacts) of DAT associated with disease
2) Confidence 0.13 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.43 Pain Relevance 0.26
That is, Mn inhibited [3H]-WIN 35,428 binding to DAT in neuronal membranes from rat striatum.
Mn Binding (binding) of DAT in striatum
3) Confidence 0.11 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.21 Pain Relevance 0.20
Consistent with this hypothesis, a direct inhibitory effect of Mn on radioligand binding to DAT was demonstrated in the same study.
Mn Binding (binding) of DAT
4) Confidence 0.11 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.22 Pain Relevance 0.22
Because this action on dopaminergic markers is mediated by DAT, these results provide evidence that Mn interacts directly with DAT and are consistent with other studies that indicate an interaction of Mn with DAT (Anderson et al. 2007; Chen et al. 2006; Ingersoll et al. 1999).


Mn Binding (interaction) of DAT
5) Confidence 0.10 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0 Pain Relevance 0.48
However, a firm conclusion that chronic Mn results in the loss of DAT and presumably dopamine neuron terminals in the striatum cannot be made because [11C]-nomifensine is not a selective DAT ligand and because Mn can directly inhibit ligand binding to DAT.
Mn Binding (binding) of DAT in striatum associated with dopamine
6) Confidence 0.08 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0 Pain Relevance 0.63
This procedure was not performed by Eriksson et al. (1992a); thus, the effect of Mn on the [3H]-mazindol autoradiography results were a combination of DAT and other monoaminergic uptake sites. c) As pointed out, even if [3H]-mazindol was made selective for DAT by including antagonists for other monoaminergic transporters, a reduction in [3H]-mazindol binding to DAT would not necessarily reflect dopamine terminal loss, but it could represent a competitive inhibition of Mn with radioligand binding to DAT as shown by Chen et al. (2006).
Mn Binding (binding) of DAT associated with dopamine, antagonist and monoamine
7) Confidence 0.08 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox